ENVVENO MEDICAL CORP (NVNO) Stock Price, Quote, News and Overview
NASDAQ:NVNO - Nasdaq - US29415J1060 - Common Stock - Currency: USD
NVNO Quote, Performance and Key Statistics
NASDAQ:NVNO (2/21/2025, 8:00:01 PM)
3.77
-0.05 (-1.31%)
The current stock price of NVNO is 3.77 USD. In the past month the price increased by 8.02%. In the past year, price decreased by -35.56%.
NVNO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About NVNO
Company Profile
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The firm's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
Company Info
ENVVENO MEDICAL CORP
70 Doppler
Irvine CALIFORNIA US
CEO: Robert Berman
Employees: 31
Company Website: https://envveno.com/
Investor Relations: https://envveno.com/investors/
Phone: 19492612900
ENVVENO MEDICAL CORP / NVNO FAQ
What is the stock price of ENVVENO MEDICAL CORP today?
The current stock price of NVNO is 3.77 USD. The price decreased by -1.31% in the last trading session.
What is the ticker symbol for ENVVENO MEDICAL CORP stock?
The exchange symbol of ENVVENO MEDICAL CORP is NVNO and it is listed on the Nasdaq exchange.
On which exchange is NVNO stock listed?
NVNO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENVVENO MEDICAL CORP stock?
7 analysts have analysed NVNO and the average price target is 16.83 USD. This implies a price increase of 346.42% is expected in the next year compared to the current price of 3.77. Check the ENVVENO MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENVVENO MEDICAL CORP worth?
ENVVENO MEDICAL CORP (NVNO) has a market capitalization of 66.13M USD. This makes NVNO a Micro Cap stock.
How many employees does ENVVENO MEDICAL CORP have?
ENVVENO MEDICAL CORP (NVNO) currently has 31 employees.
What are the support and resistance levels for ENVVENO MEDICAL CORP (NVNO) stock?
ENVVENO MEDICAL CORP (NVNO) has a support level at 3.17 and a resistance level at 5.18. Check the full technical report for a detailed analysis of NVNO support and resistance levels.
Should I buy ENVVENO MEDICAL CORP (NVNO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVNO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVNO, evaluating the profitability, health, valuation and growth aspects
- ENVVENO MEDICAL CORP (NVNO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENVVENO MEDICAL CORP (NVNO) Sales and EPS estimates to see what analysts future expectations are.
- ENVVENO MEDICAL CORP (NVNO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENVVENO MEDICAL CORP (NVNO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENVVENO MEDICAL CORP (NVNO) Stock Chart to make your own analysis
- ENVVENO MEDICAL CORP (NVNO) Latest news and press-releases to stay up to date.
Does ENVVENO MEDICAL CORP (NVNO) stock pay dividends?
NVNO does not pay a dividend.
When does ENVVENO MEDICAL CORP (NVNO) report earnings?
ENVVENO MEDICAL CORP (NVNO) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of ENVVENO MEDICAL CORP (NVNO)?
ENVVENO MEDICAL CORP (NVNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.33).
What is the Short Interest ratio of ENVVENO MEDICAL CORP (NVNO) stock?
The outstanding short interest for ENVVENO MEDICAL CORP (NVNO) is 2.6% of its float. Check the ownership tab for more information on the NVNO short interest.
NVNO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NVNO. When comparing the yearly performance of all stocks, NVNO is a bad performer in the overall market: 79.35% of all stocks are doing better.
NVNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NVNO. While NVNO has a great health rating, there are worries on its profitability.
NVNO Financial Highlights
Over the last trailing twelve months NVNO reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 38.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.15% | ||
| ROE | -44.84% | ||
| Debt/Equity | 0 |
NVNO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to NVNO. The Buy consensus is the average rating of analysts ratings from 7 analysts.